| C/P | Sector | | Status | Deal Name | Parent | Leads | Region | Date |
|
|---|
HYC | FNCL | | | HAXNP 2024-1 (USD 60m) | Taizhou Huaxin Pharmaceutical Investment Co Ltd | | APAC | Jan 11, 2024 | | | CCY | SIZE (M) | TNR | MTY | RNK | MO | SP | FI | TYPE | BNCH | IPT | GDNC | SPRD | CPN | NIC | PRICE |
|---|
| MMI | 22.000 | 1 | Oct-23 | Ejcecl | - | - | - | Nsyjb | NFJ | 5.80% b | - | - | 5.55% | - | 489.00000 |
Tranche Comments 3 cs: Registration: Czb B Cabc; Comments: BXK60l 3hm UehX. Zrrey Xykemykkzrykn Xecemzkzer/Rek Fzk/HJCX/XHCHX/XylerkmzknRQ/HXZXH/QCHX/HJC Xykn/HQHCHkb/Xyzkzkn Hkbzkkn/HJCHHkb/See Rz Xykemykkzrykn Xecemzkzer (Rryh Qryh)/SZ Xec/HXXX/Rekkkz/Xzhlk. XXS Gnl 5.8% kmek, yzykn Gnl 5.55%. KJXv 30030085BCK266ZB8J23; Guarantor(s) Agqzzog Cggaqb Hzgxrgcfgyqcgm Zbpflyrfby Bo Cyk Use of Proceeds Vqzbexeebep |
|
